Aktis Oncology Unveils Miniprotein Radiopharma Platform, Highlights Nectin-4 and B7-H3 Programs
Aktis Oncology (NASDAQ:AKTS) executives outlined the company's strategy to expand the use of targeted radiopharmaceuticals beyond the limited set of currently approved products, emphasizing a novel...